CN103997894B - 乳癌的治疗 - Google Patents

乳癌的治疗 Download PDF

Info

Publication number
CN103997894B
CN103997894B CN201280048192.2A CN201280048192A CN103997894B CN 103997894 B CN103997894 B CN 103997894B CN 201280048192 A CN201280048192 A CN 201280048192A CN 103997894 B CN103997894 B CN 103997894B
Authority
CN
China
Prior art keywords
substituted
alkyl
compound
formula
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280048192.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103997894A (zh
Inventor
A·A·普罗特
J·瑞彻
D·克齐兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maddie Wilson Prostate Treatment Co Ltd
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Medivation Prostate Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103997894(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Colorado Boulder, Medivation Prostate Therapeutics LLC filed Critical University of Colorado Boulder
Publication of CN103997894A publication Critical patent/CN103997894A/zh
Application granted granted Critical
Publication of CN103997894B publication Critical patent/CN103997894B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280048192.2A 2011-07-29 2012-07-27 乳癌的治疗 Active CN103997894B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
US61/513,361 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
CN103997894A CN103997894A (zh) 2014-08-20
CN103997894B true CN103997894B (zh) 2016-08-24

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280048192.2A Active CN103997894B (zh) 2011-07-29 2012-07-27 乳癌的治疗

Country Status (18)

Country Link
US (4) US9517229B2 (https=)
EP (4) EP3430907A1 (https=)
JP (2) JP6158180B2 (https=)
KR (1) KR101923250B1 (https=)
CN (1) CN103997894B (https=)
BR (1) BR112014002200A2 (https=)
CA (1) CA2843417C (https=)
CY (1) CY1121038T1 (https=)
DK (1) DK2739153T3 (https=)
EA (1) EA028452B1 (https=)
ES (1) ES2696074T3 (https=)
HU (1) HUE040524T2 (https=)
MX (1) MX359664B (https=)
PH (1) PH12014500248B1 (https=)
PL (1) PL2739153T3 (https=)
PT (1) PT2739153T (https=)
SI (1) SI2739153T1 (https=)
WO (1) WO2013066440A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101923250B1 (ko) * 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
SG11201501870RA (en) 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
SG11201704425TA (en) * 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
PT4013412T (pt) 2019-08-12 2026-03-18 Deciphera Pharmaceuticals Llc Ripretinib para o tratamento de tumores estromais gastrointestinais
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
EP4188330A4 (en) * 2020-08-03 2024-09-04 Oncocyte Corporation CLASSIFICATION OF TUMORS AND PREDICTION OF RESPONSE
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454002A (zh) * 2006-03-27 2009-06-10 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
WO2010099238A1 (en) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP4644737B2 (ja) 2005-05-13 2011-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールヒダントイン化合物
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
KR101456722B1 (ko) * 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
DK2297359T3 (en) 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
WO2011022316A1 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
KR101923250B1 (ko) * 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
AU2012345789B2 (en) 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
US10175240B2 (en) 2012-08-23 2019-01-08 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101454002A (zh) * 2006-03-27 2009-06-10 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
WO2010099238A1 (en) * 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds

Also Published As

Publication number Publication date
EP3791724A1 (en) 2021-03-17
PT2739153T (pt) 2018-11-28
PH12014500248B1 (en) 2018-08-31
WO2013066440A1 (en) 2013-05-10
EA028452B1 (ru) 2017-11-30
JP2014524934A (ja) 2014-09-25
US9517229B2 (en) 2016-12-13
HK1198867A1 (en) 2015-06-19
JP6158180B2 (ja) 2017-07-05
JP2017141269A (ja) 2017-08-17
EP3430907A1 (en) 2019-01-23
EA201400178A1 (ru) 2014-11-28
PH12014500248A1 (en) 2014-03-17
CY1121038T1 (el) 2019-12-11
US20190262315A1 (en) 2019-08-29
MX359664B (es) 2018-10-05
DK2739153T3 (en) 2018-12-03
ES2696074T3 (es) 2019-01-14
HK1201413A1 (en) 2015-09-04
EP2739153B1 (en) 2018-08-22
HUE040524T2 (hu) 2019-03-28
SI2739153T1 (sl) 2018-12-31
CA2843417A1 (en) 2013-05-10
BR112014002200A2 (pt) 2017-03-07
US10111861B2 (en) 2018-10-30
US20140296312A1 (en) 2014-10-02
PL2739153T3 (pl) 2019-04-30
KR101923250B1 (ko) 2018-11-28
KR20140107174A (ko) 2014-09-04
EP3610731A1 (en) 2020-02-19
US20170087132A1 (en) 2017-03-30
CN103997894A (zh) 2014-08-20
WO2013066440A9 (en) 2013-07-18
CA2843417C (en) 2018-08-21
EP2739153A4 (en) 2015-03-11
MX2014001218A (es) 2014-08-22
EP2739153A1 (en) 2014-06-11
US20210069154A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
CN103997894B (zh) 乳癌的治疗
WO2022133731A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
CN101370497B (zh) 包含parp抑制剂和细胞毒性剂的联合产品及用途
JP2020193234A (ja) 前立腺癌およびアンドロゲン受容体関連病態の治療のためのアンドロゲン受容体の調節剤
JP6433085B2 (ja) がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
US9464093B2 (en) Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer
WO2013067142A1 (en) Compounds and treatment methods
WO2013067151A1 (en) Treatment methods using diarylthiohydantoin derivatives
CN105579439B (zh) 辐射减轻性药物制剂
JP2010514734A (ja) 腸障害の治療のためのイソソルビドモノニトレート誘導体
JP2022527451A (ja) Ｐｋｍ２モジュレーターおよびその使用方法
HK1201413B (en) Treatment of breast cancer
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
WO2025237421A1 (zh) 作为雄激素受体调节剂的新型偶联分子及其应用
JP2019189625A (ja) がんの治療のためのｐｉｍキナーゼ阻害剤と組み合わせたペプチドエポキシケトンプロテアソーム阻害剤
HK1198867B (en) Treatment of breast cancer
HK1229744B (zh) 2-乙酰基萘并[2，3-b]呋喃-4，9-二酮用於治疗癌症的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201413

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: American California

Co-patentee after: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee after: Mehdi Vee Xun prostate therapeutics limited liability company

Address before: American California

Co-patentee before: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee before: Mai Diweixun prostate treatment limited company

CP01 Change in the name or title of a patent holder
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1201413

Country of ref document: HK

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: American Colorado

Co-patentee after: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee after: Maddie Wilson prostate treatment Co., Ltd.

Address before: American California

Co-patentee before: Colorado University Administrative Affairs Committee (Yi Ge body corporate)

Patentee before: Mehdi Vee Xun prostate therapeutics limited liability company

CP02 Change in the address of a patent holder

Address after: New York State, USA

Patentee after: Maddie Wilson prostate treatment Co.,Ltd.

Patentee after: THE REGENTS OF THE University OF COLORADO

Address before: Colorado, USA

Patentee before: Maddie Wilson prostate treatment Co.,Ltd.

Patentee before: THE REGENTS OF THE University OF COLORADO

CP02 Change in the address of a patent holder